Allogene Therapeutics
Zhe (Joanne) Li is a Principal Scientist at Allogene Therapeutics, where the focus is on developing allogeneic CAR-T therapies for solid tumors since June 2021. Prior to this role, Zhe served as an NIH T32 Postdoctoral Fellow at UCLA, under Dr. Lili Yang, working on stem cell engineered cell products for cancer immunotherapy and investigating molecular control of antitumor immunity. Zhe also has experience as a Graduate Research Assistant at the University of Southern California, completing a Ph.D. in Pharmaceutical Sciences in 2018, and as a Research Intern at Genentech, where genetic modifications of stem cells were performed. Zhe began academic pursuits in biology at Peking University, earning a Bachelor’s Degree in 2012.
This person is not in the org chart
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.